{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T11:22:10Z","timestamp":1793013730755,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012399","name":"BARDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.vaccine.2021.10.010","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T11:23:10Z","timestamp":1635160990000},"page":"6930-6935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Antibody responses against heterologous A\/H5N1 strains for an MF59-adjuvanted cell culture\u2013derived A\/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects"],"prefix":"10.1016","volume":"39","author":[{"given":"Pornthep","family":"Chanthavanich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Versage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Van Twuijver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hohenboken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.vaccine.2021.10.010_b0005","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1056\/NEJMp038238","article-title":"Influenza vaccine\u2014outmaneuvering antigenic shift and drift","volume":"350","author":"Treanor","year":"2004","journal-title":"N Engl J Med."},{"issue":"12","key":"10.1016\/j.vaccine.2021.10.010_b0010","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1086\/375056","article-title":"Pandemic influenza and the global vaccine supply","volume":"36","author":"Fedson","year":"2003","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2021.10.010_b0015","series-title":"National strategy for pandemic influenza","author":"Homeland Security Council","year":"2005"},{"issue":"32","key":"10.1016\/j.vaccine.2021.10.010_b0020","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1016\/j.vaccine.2012.05.013","article-title":"A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A\/H1N1 influenza vaccine in adult and elderly populations","volume":"30","author":"Hatz","year":"2012","journal-title":"Vaccine."},{"issue":"3","key":"10.1016\/j.vaccine.2021.10.010_b0025","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.vaccine.2009.10.019","article-title":"Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1\/2 clinical trial","volume":"28","author":"Keitel","year":"2010","journal-title":"Vaccine."},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.010_b0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-018-0079-z","article-title":"Cell culture-derived influenza vaccines in the severe 2017\u20132018 epidemic season: a step towards improved influenza vaccine effectiveness","volume":"3","author":"Barr","year":"2018","journal-title":"npj Vaccines"},{"issue":"10","key":"10.1016\/j.vaccine.2021.10.010_b0035","doi-asserted-by":"crossref","first-page":"e1006682","DOI":"10.1371\/journal.ppat.1006682","article-title":"A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine","volume":"13","author":"Wu","year":"2017","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.vaccine.2021.10.010_b0040","doi-asserted-by":"crossref","first-page":"e92153","DOI":"10.1371\/journal.pone.0092153","article-title":"Low 2012\u201313 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses","volume":"9","author":"Skowronski","year":"2014","journal-title":"PLoS ONE"},{"issue":"48","key":"10.1016\/j.vaccine.2021.10.010_b0045","doi-asserted-by":"crossref","first-page":"6583","DOI":"10.1016\/j.vaccine.2014.06.045","article-title":"Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing","volume":"32","author":"Donis","year":"2014","journal-title":"Vaccine."},{"issue":"47","key":"10.1016\/j.vaccine.2021.10.010_b0050","doi-asserted-by":"crossref","first-page":"12578","DOI":"10.1073\/pnas.1712377114","article-title":"Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains","volume":"114","author":"Zost","year":"2017","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2021.10.010_b0055","doi-asserted-by":"crossref","unstructured":"Rajaram S, Van Boxmeer J, Leav B, Suphaphiphat P, Iheanacho I, Kistler K. Retrospective evaluation of mismatch from egg-based isolation of influenza strains compared to cell-based isolation and the possible implications for vaccine effectiveness. IDWeek 2018. San Francisco, CA2018. p. Abstract 2556.","DOI":"10.1093\/ofid\/ofy209.164"},{"issue":"2","key":"10.1016\/j.vaccine.2021.10.010_b0060","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/0042-6822(87)90418-1","article-title":"Host cell-mediated variation in H3N2 influenza viruses","volume":"156","author":"Katz","year":"1987","journal-title":"Virology"},{"issue":"11","key":"10.1016\/j.vaccine.2021.10.010_b0065","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1099\/0022-1317-74-11-2513","article-title":"Comparison of 10 influenza A (H1N1 and H3N2) haemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses","volume":"74","author":"Rocha","year":"1993","journal-title":"J Gen Virol."},{"key":"10.1016\/j.vaccine.2021.10.010_b0070","doi-asserted-by":"crossref","unstructured":"Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017-2018. J Infect Dis. 2019;220:1255-64.","DOI":"10.1093\/infdis\/jiy716"},{"key":"10.1016\/j.vaccine.2021.10.010_b0075","unstructured":"Eick-Cost A, Hu Z. Relative effectiveness of cell-based influenza vaccines compared to egg-based influenza vaccines, active component U.S. Service members, 2017-18 season. International Conference on Emerging Infectious Diseases. Atlanta, GA2018. p. 54. Abstr. 129."},{"key":"10.1016\/j.vaccine.2021.10.010_b0080","doi-asserted-by":"crossref","unstructured":"Klein NP, Fireman B, Goddard K, Zerbo O, Asher J, Zhou J, et al. LB15. Vaccine effectiveness of Flucelvax relative to inactivated influenza vaccine during the 2017\u201318 influenza season in Northern California. Open Forum Infect Dis. 2018;5:S764-S.","DOI":"10.1093\/ofid\/ofy229.2189"},{"key":"10.1016\/j.vaccine.2021.10.010_b0085","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/INF.0b013e31824bb179","article-title":"Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age","volume":"31","author":"Vesikari","year":"2012","journal-title":"Pediatr Infect Dis J."},{"issue":"sep15 3","key":"10.1016\/j.vaccine.2021.10.010_b0090","doi-asserted-by":"crossref","first-page":"b3680","DOI":"10.1136\/bmj.b3680","article-title":"Recommendations for the administration of influenza vaccine in children allergic to egg","volume":"339","author":"Erlewyn-Lajeunesse","year":"2009","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.vaccine.2021.10.010_b0095","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.vaccine.2019.10.053","article-title":"Priming with MF59 adjuvanted versus nonadjuvanted seasonal influenza vaccines in children\u2014a systematic review and a meta-analysis","volume":"38","author":"Patel","year":"2020","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.10.010_b0100","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.ijid.2019.05.009","article-title":"Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children","volume":"85","author":"Patel","year":"2019","journal-title":"Int J Infect Dis."},{"issue":"27","key":"10.1016\/j.vaccine.2021.10.010_b0105","doi-asserted-by":"crossref","first-page":"11169","DOI":"10.1073\/pnas.1107941108","article-title":"Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88","volume":"108","author":"Seubert","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"8","key":"10.1016\/j.vaccine.2021.10.010_b0110","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.4049\/jimmunol.180.8.5402","article-title":"The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells","volume":"180","author":"Seubert","year":"2008","journal-title":"Journal of immunology (Baltimore, Md"},{"issue":"26","key":"10.1016\/j.vaccine.2021.10.010_b0115","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1016\/j.vaccine.2008.03.093","article-title":"Safety of MF59 adjuvant","volume":"26","author":"Schultze","year":"2008","journal-title":"Vaccine."},{"issue":"15","key":"10.1016\/j.vaccine.2021.10.010_b0120","article-title":"Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus","volume":"2","author":"Khurana","year":"2010","journal-title":"Sci Transl Medi."},{"issue":"9","key":"10.1016\/j.vaccine.2021.10.010_b0125","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.vaccine.2010.12.090","article-title":"Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes","volume":"29","author":"Calabro","year":"2011","journal-title":"Vaccine."},{"issue":"52","key":"10.1016\/j.vaccine.2021.10.010_b0130","doi-asserted-by":"crossref","first-page":"21095","DOI":"10.1073\/pnas.1319784110","article-title":"The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination","volume":"110","author":"Vono","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"29","key":"10.1016\/j.vaccine.2021.10.010_b0135","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59\u2014an innately attractive adjuvant formulation","volume":"30","author":"O\u2019Hagan","year":"2012","journal-title":"Vaccine."},{"issue":"85","key":"10.1016\/j.vaccine.2021.10.010_b0140","doi-asserted-by":"crossref","first-page":"85ra48","DOI":"10.1126\/scitranslmed.3002336","article-title":"MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines","volume":"3","author":"Khurana","year":"2011","journal-title":"Sci Transl Med"},{"issue":"9272","key":"10.1016\/j.vaccine.2021.10.010_b0145","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(00)05066-2","article-title":"Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A\/Duck\/Singapore\/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza","volume":"357","author":"Nicholson","year":"2001","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.010_b0150","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.vaccine.2014.10.085","article-title":"Safety and immunogenicity of an MF59-adjuvanted A\/H1N1 pandemic influenza vaccine in children from three to seventeen years of age","volume":"33","author":"Knuf","year":"2015","journal-title":"Vaccine."},{"issue":"2","key":"10.1016\/j.vaccine.2021.10.010_b0155","doi-asserted-by":"crossref","first-page":"e4384","DOI":"10.1371\/journal.pone.0004384","article-title":"MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults","volume":"4","author":"Banzhoff","year":"2009","journal-title":"PLoS ONE"},{"issue":"19","key":"10.1016\/j.vaccine.2021.10.010_b0160","doi-asserted-by":"crossref","first-page":"7962","DOI":"10.1073\/pnas.0903181106","article-title":"Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine","volume":"106","author":"Galli","year":"2009","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.vaccine.2021.10.010_b0165","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ijid.2019.03.026","article-title":"Immunogenicity of aIIV3, MF59-adjuvanted seasonal trivalent influenza vaccine, in older adults \u226565 years of age: Meta-analysis of cumulative clinical experience","volume":"85","author":"Nicolay","year":"2019","journal-title":"Int J Infect Dis."},{"issue":"25","key":"10.1016\/j.vaccine.2021.10.010_b0170","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1016\/j.vaccine.2010.04.030","article-title":"Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates","volume":"28","author":"Ansaldi","year":"2010","journal-title":"Vaccine."},{"issue":"12","key":"10.1016\/j.vaccine.2021.10.010_b0175","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.vaccine.2008.01.019","article-title":"Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses","volume":"26","author":"Ansaldi","year":"2008","journal-title":"Vaccine."},{"issue":"15","key":"10.1016\/j.vaccine.2021.10.010_b0180","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1010331","article-title":"Oil-in-water emulsion adjuvant with influenza vaccine in young children","volume":"365","author":"Vesikari","year":"2011","journal-title":"N Engl J Med."},{"issue":"5","key":"10.1016\/j.vaccine.2021.10.010_b0185","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S2213-2600(18)30108-5","article-title":"Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial","volume":"6","author":"Vesikari","year":"2018","journal-title":"Lancet Respir Med."},{"issue":"5","key":"10.1016\/j.vaccine.2021.10.010_b0190","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1586\/14760584.6.5.699","article-title":"MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection","volume":"6","author":"O\u2019Hagan","year":"2007","journal-title":"Expert review of vaccines."},{"issue":"49","key":"10.1016\/j.vaccine.2021.10.010_b0195","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2009.08.101","article-title":"MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database","volume":"27","author":"Pellegrini","year":"2009","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2021.10.010_b0200","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/INF.0000000000002345","article-title":"Safety, tolerability and immunogenicity of an MF59-adjuvanted, cell culture-derived, A\/H5N1, subunit influenza virus vaccine: results from a dose-finding clinical trial in healthy pediatric subjects","volume":"38","author":"Chanthavanich","year":"2019","journal-title":"Pediatr Infect Dis J."},{"key":"10.1016\/j.vaccine.2021.10.010_b0205","series-title":"Guideline on influenza vaccines: non-clinical and clinical module","author":"Committee for Medicinal Products for Human Use","year":"2016"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.010_b0210","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1128\/JCM.37.4.937-943.1999","article-title":"Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays","volume":"37","author":"Rowe","year":"1999","journal-title":"J Clin Microbiol."},{"issue":"5","key":"10.1016\/j.vaccine.2021.10.010_b0215","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1128\/JCM.03575-13","article-title":"Detection of nonhemagglutinating influenza a(h3) viruses by enzyme-linked immunosorbent assay in quantitative influenza virus culture","volume":"52","author":"van Baalen","year":"2014","journal-title":"J Clin Microbiol."},{"issue":"3","key":"10.1016\/j.vaccine.2021.10.010_b0220","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/biot.201300225","article-title":"Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines","volume":"9","author":"Nakowitsch","year":"2014","journal-title":"Biotechnol J."},{"issue":"5","key":"10.1016\/j.vaccine.2021.10.010_b0225","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1080\/21645515.2015.1016666","article-title":"Cell culture-based influenza vaccines: A necessary and indispensable investment for the future","volume":"11","author":"Hegde","year":"2015","journal-title":"Hum Vaccin Immunother."},{"issue":"1","key":"10.1016\/j.vaccine.2021.10.010_b0230","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.vaccine.2016.11.060","article-title":"ViroSpot microneutralization assay for antigenic characterization of human influenza viruses","volume":"35","author":"van Baalen","year":"2017","journal-title":"Vaccine."},{"issue":"6","key":"10.1016\/j.vaccine.2021.10.010_b0235","doi-asserted-by":"crossref","first-page":"e0131531","DOI":"10.1371\/journal.pone.0131531","article-title":"Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children","volume":"10","author":"Verschoor","year":"2015","journal-title":"PLoS ONE"},{"issue":"4","key":"10.1016\/j.vaccine.2021.10.010_b0240","doi-asserted-by":"crossref","first-page":"707","DOI":"10.3390\/vaccines2040707","article-title":"Overview of serological techniques for influenza vaccine evaluation: past, present and future","volume":"2","author":"Trombetta","year":"2014","journal-title":"Vaccines (Basel)."},{"issue":"9","key":"10.1016\/j.vaccine.2021.10.010_b0245","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00750-20","article-title":"Comparability of titers of antibodies against seasonal influenza virus strains as determined by hemagglutination inhibition and microneutralization assays","volume":"58","author":"Heeringa","year":"2020","journal-title":"J Clin Microbiol."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21013177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21013177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:02:41Z","timestamp":1759402961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21013177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":49,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0264410X21013177"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.010","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody responses against heterologous A\/H5N1 strains for an MF59-adjuvanted cell culture\u2013derived A\/H5N1 (aH5N1c) influenza vaccine in healthy pediatric subjects","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}